Skip to main content

Kaempferol and Apigenin suppresses the stemness properties of TNBC cells by modulating Sirtuins

Molecular Diversity volume 26, pages 3225–3240 (2022)Cite this article

Abstract

Sirtuins (SIRTs) overexpression serves as a potential therapeutic target for TNBC because it is associated with bioactivities of cancer stem cells (CSCs), resistance to chemotherapy, and metastasis. Irrespective of the availability of synthetic SIRT inhibitors, new SIRT inhibitors with enhanced potency and lesser side effects serve as current unmet needs. Therefore, bioactive dietary compounds; kaempferol (KMP) and apigenin (API) were investigated for their anti-SIRTs potential. We observed KMP and API inhibits cellular proliferation by DNA damage and S-phase cell cycle arrest in TNBC Cells. They also suppress stemness properties in TNBCs as observed in experiments of mammosphere formation and clonogenic potential. Our mechanistic approach indicated that KMP and API inhibited SIRT3 and SIRT6 proteins, as evidenced by our in silico and in vitro experiment. Collectively, our studies suggest that KMP and API are promising candidates to be further developed as sirtuin modulators against TNBCs.

Graphical abstract

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11

References

  1. Dai X, Xiang L, Li T, Bai Z (2016) Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 7:1281–1294. https://doi.org/10.7150/jca.13141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938–1948. https://doi.org/10.1056/NEJMra1001389

    Article  CAS  PubMed  Google Scholar 

  3. Sharma P (2018) Update on the treatment of early-stage triple-negative breast cancer. Curr Treat Options Oncol 19:22. https://doi.org/10.1007/s11864-018-0539-8

    Article  PubMed  Google Scholar 

  4. Kim C, Gao R, Sei E et al (2018) Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173:879–893. https://doi.org/10.1016/j.cell.2018.03.041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL (2013) Sirtuin-3 (SIRT3) and the hallmarks of cancer. Genes Cancer 4:164–171. https://doi.org/10.1177/1947601913486351

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ioris RM, Galié M, Ramadori G et al (2017) SIRT6 suppresses cancer stem-like capacity in tumors with PI3K activation independently of its deacetylase activity. Cell Rep 18:1858–1868. https://doi.org/10.1016/j.celrep.2017.01.065

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bosch-Presegué L, Vaquero A (2011) The dual role of sirtuins in cancer. Genes Cancer 2:648–662. https://doi.org/10.1177/1947601911417862

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Khongkow M, Olmos Y, Gong C et al (2013) SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis 34:1476–1486. https://doi.org/10.1093/carcin/bgt098

    Article  CAS  PubMed  Google Scholar 

  9. Ganai SA, Farooq Z, Banday S, Altaf M (2018) In silico approaches for investigating the binding propensity of apigenin and luteolin against class I HDAC isoforms. Future Med Chem 10:1925–1945. https://doi.org/10.4155/fmc-2018-0020

    Article  CAS  PubMed  Google Scholar 

  10. Tseng T-H, Chien M-H, Lin W-L et al (2017) Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21(WAF1/CIP1) expression. Environ Toxicol 32:434–444. https://doi.org/10.1002/tox.22247

    Article  CAS  PubMed  Google Scholar 

  11. Marfe G, Tafani M, Indelicato M et al (2009) Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J Cell Biochem 106:643–650. https://doi.org/10.1002/jcb.22044

    Article  CAS  PubMed  Google Scholar 

  12. Ashraf R, Hamidullah HM et al (2017) Coumarin-chalcone hybrid instigates DNA damage by minor groove binding and stabilizes p53 through post translational modifications. Sci Rep. https://doi.org/10.1038/srep45287

    Article  PubMed  PubMed Central  Google Scholar 

  13. Meeran SM, Ahmed A, Tollefsbol TO (2010) Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenet 1:101–116

    Article  CAS  Google Scholar 

  14. Sinha S, Sharma S, Vora J et al (2018) Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling. J Ethnopharmacol 217:23–35. https://doi.org/10.1016/j.jep.2018.02.006

    Article  CAS  PubMed  Google Scholar 

  15. Shukla S, Sinha S, Khan S et al (2016) Cucurbitacin B inhibits the stemness and metastatic abilities of NSCLC via downregulation of canonical Wnt/β-catenin signaling axis. Sci Rep. https://doi.org/10.1038/srep21860

    Article  PubMed  PubMed Central  Google Scholar 

  16. Szklarczyk D, Santos A, von Mering C et al (2016) STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucl Acids Res 44:D380–D384. https://doi.org/10.1093/nar/gkv1277

    Article  CAS  PubMed  Google Scholar 

  17. Wang X, Shen Y, Wang S et al (2017) PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucl Acids Res 45:W356–W360. https://doi.org/10.1093/nar/gkx374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Davies M, Nowotka M, Papadatos G et al (2015) ChEMBL web services: streamlining access to drug discovery data and utilities. Nucl Acids Res 43:W612–W620. https://doi.org/10.1093/nar/gkv352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sinha S, Patel S, Athar M et al (2019) Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: an in silico and in vitro study. Int J Biol Macromol 140:454–468. https://doi.org/10.1016/j.ijbiomac.2019.08.061

    Article  CAS  PubMed  Google Scholar 

  20. Piñero J, Bravo Á, Queralt-Rosinach N et al (2017) DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucl Acids Res 45:D833–D839. https://doi.org/10.1093/nar/gkw943

    Article  CAS  PubMed  Google Scholar 

  21. Safran M, Solomon I, Shmueli O et al (2002) GeneCardsTM 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics 18:1542–1543. https://doi.org/10.1093/BIOINFORMATICS/18.11.1542

    Article  CAS  PubMed  Google Scholar 

  22. Shannon P, Markiel A, Ozier O et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498–2504. https://doi.org/10.1101/gr.1239303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Szklarczyk D, Gable AL, Lyon D et al (2019) STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucl Acids Res 47:D607–D613. https://doi.org/10.1093/nar/gky1131

    Article  CAS  PubMed  Google Scholar 

  24. Mi H, Ebert D, Muruganujan A et al (2021) PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API. Nucl Acids Res 49:D394–D403. https://doi.org/10.1093/NAR/GKAA1106

    Article  CAS  PubMed  Google Scholar 

  25. Parmar P, Rao P, Sharma A et al (2021) Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow. Mol Divers. https://doi.org/10.1007/s11030-021-10233-3

    Article  PubMed  PubMed Central  Google Scholar 

  26. Genheden S, Ryde U (2015) The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Exp Opin Drug Discov 10:449–461

    Article  CAS  Google Scholar 

  27. Schafer KA (1998) The cell cycle: a review. Vet Pathol 35:461–478. https://doi.org/10.1177/030098589803500601

    Article  CAS  PubMed  Google Scholar 

  28. Golias C, Charalabopoulos A, Charalabopoulos K (2004) Cell proliferation and cell cycle control: a mini review. Int J Clin Pract 58:1134–1141. https://doi.org/10.1111/j.1742-1241.2004.00284.x

    Article  CAS  PubMed  Google Scholar 

  29. Madunić J, Madunić IV, Gajski G et al (2018) Apigenin: a dietary flavonoid with diverse anticancer properties. Cancer Lett 413:11–22. https://doi.org/10.1016/j.canlet.2017.10.041

    Article  CAS  PubMed  Google Scholar 

  30. Sancho P, Barneda D, Heeschen C (2016) Hallmarks of cancer stem cell metabolism. Br J Cancer 114:1305–1312. https://doi.org/10.1038/bjc.2016.152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ajona D, Ortiz-Espinosa S, Pio R, Lecanda F (2019) Complement in metastasis: a comp in the camp. Front Immunol 10:669. https://doi.org/10.3389/fimmu.2019.00669

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Tian J, al RaffaDai FM et al (2018) Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Br J Cancer. https://doi.org/10.1038/s41416-018-0287-3

    Article  PubMed  PubMed Central  Google Scholar 

  33. Han L, Shi S, Gong T et al (2013) Cancer stem cells: therapeutic implications and perspectives in cancer therapy. Acta Pharm Sin B 3:65–75. https://doi.org/10.1016/j.apsb.2013.02.006

    Article  Google Scholar 

  34. Yan D, Lian D, Heng-wen C (2019) Network pharmacology-based prediction and verification of the targets and mechanism for Panax Notoginseng Saponins against coronary heart disease. Evidence-based complementary and alternative medicine: eCAM.https://doi.org/10.1155/2019/6503752

  35. Carafa V, Altucci L, Nebbioso A (2019) Dual tumor suppressor and tumor promoter action of sirtuins in determining malignant phenotype. Front Pharmacol 10:38. https://doi.org/10.3389/fphar.2019.00038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Yuan H, Su L, Chen WY (2013) The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 6:1399–1416. https://doi.org/10.2147/OTT.S37750

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Angeliki C, Leonard G (2015) The multifaceted functions of sirtuins in cancer. Nat Rev Cancer 15:608–624. https://doi.org/10.1038/NRC3985

    Article  Google Scholar 

Download references

Acknowledgements

We acknowledge our host institute, B.V. Patel Pharmaceutical Education Research and Development (PERD) Centre, to provide us with the facilities to work. Author A. S. express gratitude to the Department of Science & Technology (DST), Ministry of Science and Technology, Government of India for INSPIRE fellowship (Grant no. IF190211).

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. B. V. Patel Pharmaceutical Education and Research Development (PERD) Centre, Ahmedabad, Gujarat, India

    Abhilasha Sharma, Sonam Sinha, Harshita Keswani & Neeta Shrivastava

  2. Department of Life Science, Gujarat University, Ahmedabad, Gujarat, India

    Abhilasha Sharma

  3. Kashiv Biosciences, FP 27/2,43, TP-86, BLOCK-B OPP. Apple Woods Township, SP Ring Road, 382210, Ahmedabad, Gujarat, India

    Sonam Sinha

  4. Department of Biotechnology and Biochemistry, St. Xavier’s College, Ahmedabad, India

    Harshita Keswani

  5. Shri B.V. Patel Education Trust, Ahmedabad, Gujarat, India

    Neeta Shrivastava

Authors
  1. Abhilasha Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonam Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harshita Keswani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neeta Shrivastava
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS contributed to conceptualization, data curation, methodology, writing—original draft; SS contributed to conceptualization, methodology, writing—review and editing; HK contributed to methodology; NS contributed to conceptualization, supervision, writing—review and editing.

Corresponding author

Correspondence to Neeta Shrivastava.

Ethics declarations

Conflict of interest

No potential conflict of interest was reported by the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Sinha, S., Keswani, H. et al. Kaempferol and Apigenin suppresses the stemness properties of TNBC cells by modulating Sirtuins. Mol Divers 26, 3225–3240 (2022). https://doi.org/10.1007/s11030-022-10384-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11030-022-10384-x

Keywords

  • Triple-negative breast cancer
  • Sirtuins
  • Molecular docking
  • Network pharmacology
  • Apigenin
  • Kaempferol